Gossamer Bio Inc (GOSS) last year’s performance of -5.19% is a clear signal for an entertaining trading season.

Gossamer Bio Inc (NASDAQ: GOSS) on Monday, plunged -7.91% from the previous trading day, before settling in for the closing price of $1.39. Within the past 52 weeks, GOSS’s price has moved between $0.50 and $1.55.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

The company achieved an average annual earnings per share of -183.43%. With a float of $182.60 million, this company’s outstanding shares have now reached $226.60 million.

The firm has a total of 145 workers. Let’s measure their productivity. In terms of profitability, gross margin is 98.28%, operating margin of -52.24%, and the pretax margin is -48.5%.

Gossamer Bio Inc (GOSS) Breakdown of a Key Holders of the stock

Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Gossamer Bio Inc is 19.64%, while institutional ownership is 58.93%. The most recent insider transaction that took place on Jun 24 ’24, was worth 1,260. In this transaction Chief Medical Officer of this company sold 1,908 shares at a rate of $0.66, taking the stock ownership to the 196,891 shares. Before that another transaction happened on Jun 21 ’24, when Company’s President & CEO bought 372,000 for $0.67, making the entire transaction worth $250,282. This insider now owns 5,408,073 shares in total.

Gossamer Bio Inc (GOSS) Recent Fiscal highlights

According to the Wall Street analysts, stocks earnings will be around -183.43% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 22.43% during the next five years compared to 40.29% growth over the previous five years of trading.

Gossamer Bio Inc (NASDAQ: GOSS) Trading Performance Indicators

Gossamer Bio Inc (GOSS) is currently performing well based on its current performance indicators. A quick ratio of 6.88 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.54.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.26, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.44 in one year’s time.

Technical Analysis of Gossamer Bio Inc (GOSS)

Analysing the last 5-days average volume posted by the [Gossamer Bio Inc, GOSS], we can find that recorded value of 1.51 million was better than the volume posted last year of 1.47 million. As of the previous 9 days, the stock’s Stochastic %D was 51.23%. Additionally, its Average True Range was 0.12.

During the past 100 days, Gossamer Bio Inc’s (GOSS) raw stochastic average was set at 69.60%, which indicates a significant increase from 48.19% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 86.22% in the past 14 days, which was higher than the 82.67% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $1.1646, while its 200-day Moving Average is $0.9554. Now, the first resistance to watch is $1.3700. This is followed by the second major resistance level at $1.4600. The third major resistance level sits at $1.5100. If the price goes on to break the first support level at $1.2300, it is likely to go to the next support level at $1.1800. Now, if the price goes above the second support level, the third support stands at $1.0900.

Gossamer Bio Inc (NASDAQ: GOSS) Key Stats

Market capitalization of the company is 290.84 million based on 227,221K outstanding shares. Right now, sales total 114,700 K and income totals -56,530 K. The company made 9,380 K in profit during its latest quarter, and -33,030 K in sales during its previous quarter.